BACKGROUND: Approximately, 15-20 of 40 HPVs that infect the female genital tract confer a high-risk of invasive cancer, thus HPVs account for 95% of cervix cancers. The objectives of this study were to: (i) estimate the prevalence of HPV infection in women infected with HIV in Ouagadougou, (ii) identify potential carcinogenic HPV strains and (iii) determine whether existing HPV vaccines match the isolated strains. METHODS: From May 2009 to April 2010, 250 HIV-infected women were included in this study. Each woman was screened for the presence of HPV and for HPV genotype using PCR/hybridization technique. RESULTS: Of the 250 HIV-infected women, 59.6% were infected with at least one type of HPV. High-risk HPVs were identified with the following prevalence: HPV-18 (25.0%); HPV-50'S (25.5%); HPV-30'S (20.8%); HPV-16 (4.7%); HPV-45 (3.7%). Low-risk HPVs were represented by HPV-6 (5.7%) and HPV-11 (0.9%). CONCLUSION: The issue of the study showed that the existing vaccines: Gardasil and Cervarix may be used in the country although they match only HPV-16, HPV-18, HPV-6 and HPV-11. Further investigations should be continued for the establishment of vaccine that matches all genotypes circulating in the country.
BACKGROUND: Approximately, 15-20 of 40 HPVs that infect the female genital tract confer a high-risk of invasive cancer, thus HPVs account for 95% of cervix cancers. The objectives of this study were to: (i) estimate the prevalence of HPV infection in women infected with HIV in Ouagadougou, (ii) identify potential carcinogenic HPV strains and (iii) determine whether existing HPV vaccines match the isolated strains. METHODS: From May 2009 to April 2010, 250 HIV-infectedwomen were included in this study. Each woman was screened for the presence of HPV and for HPV genotype using PCR/hybridization technique. RESULTS: Of the 250 HIV-infectedwomen, 59.6% were infected with at least one type of HPV. High-risk HPVs were identified with the following prevalence: HPV-18 (25.0%); HPV-50'S (25.5%); HPV-30'S (20.8%); HPV-16 (4.7%); HPV-45 (3.7%). Low-risk HPVs were represented by HPV-6 (5.7%) and HPV-11 (0.9%). CONCLUSION: The issue of the study showed that the existing vaccines: Gardasil and Cervarix may be used in the country although they match only HPV-16, HPV-18, HPV-6 and HPV-11. Further investigations should be continued for the establishment of vaccine that matches all genotypes circulating in the country.
Authors: H De Vuyst; N R Mugo; M H Chung; K P McKenzie; E Nyongesa-Malava; V Tenet; J W Njoroge; S R Sakr; Cjl M Meijer; P J F Snijders; F S Rana; S Franceschi Journal: Br J Cancer Date: 2012-10-02 Impact factor: 7.640
Authors: Theodora M Zohoncon; Cyrille Bisseye; Florencia W Djigma; Albert T Yonli; Tegwinde R Compaore; Tani Sagna; Djeneba Ouermi; Charlemagne M R Ouédraogo; Virginio Pietra; Jean-Baptiste Nikiéma; Simon A Akpona; Jacques Simpore Journal: Mediterr J Hematol Infect Dis Date: 2013-09-02 Impact factor: 2.576
Authors: Ina Marie Angèle Traore; Théodora Mahoukèdè Zohoncon; Adama Dembele; Florencia W Djigma; Dorcas Obiri-Yeboah; Germain Traore; Moussa Bambara; Charlemagne Ouedraogo; Yves Traore; Jacques Simpore Journal: Biomed Res Int Date: 2016-07-20 Impact factor: 3.411
Authors: Admire Chikandiwa; Helen Kelly; Bernard Sawadogo; Jean Ngou; Pedro T Pisa; Lorna Gibson; Marie-Noelle Didelot; Nicolas Meda; Helen A Weiss; Michel Segondy; Philippe Mayaud; Sinead Delany-Moretlwe Journal: PLoS One Date: 2018-05-01 Impact factor: 3.240